Rx drug word-of-mouth occurs largely offline: study

Share this article:

Less than 10% of drug-related word-of-mouth takes place online, compared with 74% happening in person, according to a Keller Fay Group report. 

The statistic should be an eye-opener for marketers obsessing over emerging digital media and blogs, explained Ed Keller, CEO, Keller Fay Group. “For some brands, it's important to facilitate talk online,” said Keller, but reaching influencers at events or by providing information they can share offline is crucial, he said.

Marketers should “recognize the power of word-of-mouth and realize that it will happen whether or not a brand is involved,” said Keller. Once marketers realize the importance of word-of-mouth, they will start working with compliance experts and the FDA to make sure communications are legitimate and ethical, explained Keller, noting a similar nervousness during the early stages of DTC advertising.

Pharma companies shouldn't necessarily be worried about ceding control of the conversation to patients, since word-of-mouth among consumers tends to be far more positive than negative, according to Keller. “Sixty-nine percent of consumers–on the receiving end–find information from peers to be credible and believable, even if they aren't experts,” he said. “The [word-of-mouth] majority isn't coming from healthcare professionals.”

Keller Fay Group is a marketing research firm with a specialty in word-of-mouth research, located in New Brunswick, NJ.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...